1. Home
  2. STAI vs MBAI Comparison

STAI vs MBAI Comparison

Compare STAI & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

STAI

ScanTech AI Systems Inc.

HOLD

Current Price

$3.30

Market Cap

10.7M

Sector

N/A

ML Signal

HOLD

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.65

Market Cap

10.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
STAI
MBAI
Founded
2011
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
10.7M
10.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
STAI
MBAI
Price
$3.30
$1.65
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
173.3K
47.1K
Earning Date
12-15-2025
02-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,881,045.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
260.24
N/A
52 Week Low
$2.32
$0.59
52 Week High
$181.40
$3.13

Technical Indicators

Market Signals
Indicator
STAI
MBAI
Relative Strength Index (RSI) 65.73 N/A
Support Level $2.32 N/A
Resistance Level $2.92 N/A
Average True Range (ATR) 0.57 0.00
MACD 0.01 0.00
Stochastic Oscillator 70.93 0.00

Price Performance

Historical Comparison
STAI
MBAI

About STAI ScanTech AI Systems Inc.

ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: